3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Impact of disease outcomes on the Assessment of SpondyloArthritis International Society Health Index (ASAS HI): a Bayesian network analysis of the DESIR cohort

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          The objective of this study is to build a structural model visualising and quantifying the interrelationships of different disease outcomes with the Assessment of SpondyloArthritis International Society Health Index (ASAS HI) in patients with axial spondyloarthritis (axSpA).

          Methods

          Cross-sectional data collected at month 72 of the Devenir des Spondylarthropathies Indifferénciées Récentes cohort was analysed. Combining prior knowledge and observed data, probabilistic Bayesian network modelling was used to study how the interplay of different disease outcomes affects the ASAS HI, which measures disease-specific overall functioning and health. Disease outcomes comprised, among others, the Ankylosing Spondylitis (AS) Disease Activity Score (ASDAS) and the Bath AS Functional Index (BASFI).

          Results

          Data of 384 patients were analysed. The obtained structure suggests that ASAS HI is determined by both patient-reported physical function (BASFI) and disease activity (ASDAS). The parameters of the structural model show that an increase of ASDAS or BASFI by 1 unit corresponds to an increase of ASAS HI by 0.70 or 1.25 units, respectively. Moreover, the model suggests that disease activity has an indirect impact on ASAS HI via BASFI. No relationship between spinal mobility or structural damage and ASAS HI was found.

          Conclusions

          This is the first structural model developed to better understand the construct and the interplay between clinically relevant outcomes related to ASAS HI in axSpA patients. It shows that disease activity and physical function have a strong impact on ASAS HI, confirming it to be a valid construct of overall functioning and health in axSpA patients.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: not found
          • Book: not found

          Causality

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Axial spondyloarthritis.

            The term axial spondyloarthritis covers both patients with non-radiographic and radiographic axial spondyloarthritis, which is also termed ankylosing spondylitis. The disease usually starts in the third decade of life with a male to female ratio of two to one for radiographic axial spondyloarthritis and of one to one for non-radiographic axial spondyloarthritis. More than 90% heritabilty has been estimated, the highest genetic association being with HLA-B27. The pathogenic role of HLA-B27 is still not clear although various hypotheses are available. On the basis of evidence from trials the cytokines tumour necrosis factor (TNF)-α and interleukin-17 appear to have a relevant role in pathogenesis. The mechanisms of interaction between inflammation and new bone formation is still not completely understood but clarification will be important for the prevention of long-term structural damage of the bone. The development of new criteria for classification and for screening of patients with axial spondyloarthritis have been crucial for the early indentification and treatment of such patients, with MRI being the most important existing imaging method. Non-steroidal anti-inflammatory drugs and TNF blockers are effective therapies. Blockade of interleukin-17 is a new and relevant treatment option.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

              After pain and stiffness, one of the most important complaints of patients with ankylosing spondylitis (AS) is disability. The main aims of treatment are to control pain but also to improve function. Various methods of assessing function exist but are either not specific for the disease or have not been adequately validated. As a result of this deficiency we developed the Bath Ankylosing Spondylitis Functional Index (BASFI) as a new approach to defining and monitoring functional ability in patients with AS. This self-assessment instrument was designed by a team of medical professionals in conjunction with patients, and consists of 8 specific questions regarding function in AS and 2 questions reflecting the patient's ability to cope with everyday life. Each question is answered on a 10 cm horizontal visual analog scale, the mean of which gives the BASFI score (0-10). The questionnaire was completed 257 times in total: once by 116 outpatients and by 47 inpatients on 3 occasions over a 3-week intensive physiotherapy course. In addition, the instrument was compared with the Dougados functional index. Patients scores covered 95% of the BASFI range, giving a normal distribution of results. In contrast only 65% of the Dougados functional index scale was used. Furthermore, over the 3 week period of inpatient treatment, the BASFI revealed a significant improvement in function (20%, p = 0.004) while there was a less impressive change in the Dougados functional index (6%, p = 0.03). This demonstrates the superior sensitivity of the BASFI: Consistency was good for both indices (p < 0.001), as was the relationship between patient perception of function and function as assessed by an external observer (p < 0.001). The BASFI satisfies the criteria required of a functional index: it is quick and easy to complete, is reliable and is sensitive to change across the whole spectrum of disease.
                Bookmark

                Author and article information

                Journal
                RMD Open
                RMD Open
                rmdopen
                rmdopen
                RMD Open
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                2056-5933
                2023
                20 December 2023
                : 9
                : 4
                : e003587
                Affiliations
                [1 ]Ringgold_39804Ruhr-Universität Bochum , Bochum, Germany
                [2 ]Ringgold_9142Rheumazentrum Ruhrgebiet , Herne, Germany
                [3 ]departmentClinical Immunology & Rheumatology , Academic Medical Center, University of Amsterdam , Amsterdam, The Netherlands
                [4 ]departmentDepartment of Rheumatology , Zuyderland Medical Center , Heerlen, The Netherlands
                [5 ]departmentDepartment of Rheumatology , Leiden University Medical Center , Leiden, The Netherlands
                [6 ]departmentDepartment of Internal Medicine, Division of Rheumatology , Maastricht University Medical Center, and the Caphri Research Institute Maastricht University , Maastricht, The Netherlands
                [7 ]departmentHopital Cochin, Rheumatology , Ringgold_72790Université Paris Descartes Faculté de Médecine , Paris, France
                [8 ]Ringgold_9142Ruhr University Bochum , Bochum, Germany
                Author notes
                [Correspondence to ] Dr Uta Kiltz; uta.kiltz@ 123456rub.de
                Author information
                http://orcid.org/0000-0003-3377-2683
                http://orcid.org/0000-0002-0577-6620
                http://orcid.org/0000-0002-5781-158X
                http://orcid.org/0000-0002-8899-9087
                http://orcid.org/0000-0003-0682-9533
                http://orcid.org/0000-0003-3009-6229
                http://orcid.org/0000-0002-9156-5095
                http://orcid.org/0000-0001-5668-4497
                Article
                rmdopen-2023-003587
                10.1136/rmdopen-2023-003587
                10748975
                38123481
                086625ab-ca5c-4ca6-aecc-679784764d4d
                © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:  http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 06 August 2023
                : 18 October 2023
                Categories
                Spondyloarthritis
                1506
                Original research
                Custom metadata
                unlocked

                spondylitis, ankylosing,patient reported outcome measures,epidemiology

                Comments

                Comment on this article